Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Keeps Wheeling And Dealing Ahead Of Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisitions boosted Forest’s 2014 sales, and the company isn’t slowing down its acquisition strategy even though it is working toward a merger with Actavis.

You may also be interested in...

Ironwood/Forest Hoping To Change The Conversation About Constipation

The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Furiex Makes Inroads In Tough-To-Treat IBS-d With Positive Phase III Eluxadoline Data

Eluxadoline met endpoints in two Phase III studies, positioning the drug for submission in a sparsely served therapeutic area, with only one FDA-approved drug and millions of patients in the U.S. and EU. Mild pancreatitis was reported in a handful of patients, but is manageable, company says.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts